Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of expression levels of multidrug resistance gene-related protein 1, P-glycoprotein and topoisomerase II on paclitaxel, gemcitabine and vinorelbine sensitivity in pulmonary cancer

Hao Zhenhua , Tan Yulong, Na Di Er Yi Min, Bai Yunbiao, Gao Kaiheng

Department of Cardiothoracic Surgery, Huashan Hospital, Fudan University, No. 12 Mid Wulumuqi Road, Shanghai 200040, PR China;

For correspondence:- Hao Zhenhua Email: haozhenhua0704@126.com

Accepted: 26 July 2019 Published: 27 August 2019

Citation: Zhenhua H, Yulong T, Min ND, Yunbiao B, Kaiheng G. Effect of expression levels of multidrug resistance gene-related protein 1, P-glycoprotein and topoisomerase II on paclitaxel, gemcitabine and vinorelbine sensitivity in pulmonary cancer. Trop J Pharm Res 2019; 18(8):1597-1601 doi: 10.4314/tjpr.v18i8.4

© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the possible correlation between drug resistance gene expression and development of drug sensitivity, and the possible clinical significance of this relationship.

Methods: A total of 100 cancer samples were surgically obtained. MTT assay was employed to determine drug sensitivity. The expression levels of drug resistance genes, multidrug resistance gene-related protein 1 (MRP1), P-glycoprotein (P-gp), and topoisomerase II (Topo II) were measured by immunohistochemistry.

Results: The expression levels of MRP1, P-gp, and Topo II genes in lung cancer were 70.0, 65.0, and 50.0 %, respectively. No significant statistical differences were observed in the expressions of MRP1, P-gp, and Topo II between human adenocarcinoma and squamous cell carcinoma (p > 0.05), but a significant difference was found in MRP1 and Topo II expressions between human adenocarcinoma or squamous carcinoma cell and small-cell lung cancer (p < 0.05). A significant positive correlation was observed between P-gp expression and resistance cisplatin, gemcitabine, vinorelbine, and paclitaxel (p < 0.05). A significant positive correlation was also found between MRP1 expression and the development of resistance to cisplatin, gemcitabine, and vinorelbine (p < 0.05), but no significant correlation was observed between MRP1 expression and the development of resistance to paclitaxel and ifosfamide (p > 0.05).

Conclusion: The up-regulated expression of MRP1 and P-gp, and the down-regulated expression of Topo II may be positively correlated with drug resistance in lung cancer patients. Thus, gene tests are recommended to guide the administration of chemotherapy.

Keywords: Lung carcinoma, Drug resistance gene, Drug sensitivity, Chemotherapy, Multidrug resistance gene-related protein